ArticleBMC complementary medicine and therapies2026
Integrated transcriptomic and functional analysis reveals selective cytotoxicity and HPV oncogene suppression induced by cinnamon essential oil in cervical cancer cells.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCervical cancer (CC) remains a major cause of cancer-related mortality among women worldwide, primarily driven by persistent infection with high-risk human papillomavirus (HPV) types. Given that natural products with selective antitumour properties offer potential for novel therapies, we evaluated the cytotoxic, antiproliferative, and molecular effects of cinnamon essential oil (CEO) on HPV-positive cervical cancer cell lines (HeLa and SiHa) and nontumorigenic keratinocytes (HaCaT).
methodsCells were exposed to a range of dilutions of CEO. Cell viability was determined by WST-1 and sulforhodamine B assays. Apoptosis was assessed using Annexin V/PI staining, caspase-3/8/9 activation, and mitochondrial membrane potential (Δψm) loss by flow cytometry. Proliferation was measured using EdU incorporation, and senescence was measured by β-galactosidase activity. Genome-wide transcriptional changes and HPV E6/E7 oncogene expression were analysed by RNA-Seq and validated with qPCR.
resultsCEO induced dose-dependent cytotoxicity and inhibited proliferation in cervical cancer cells, while HaCaT cells were significantly more resistant. Apoptosis was evidenced by Annexin V/PI positivity, activation of caspases -8, -9, and -3, and significant loss of mitochondrial membrane potential. No significant senescence induction was observed. Additionally, CEO also significantly downregulated HPV E6/E7 oncogene expression in HeLa and SiHa cells. Transcriptomic analysis revealed broad differential gene expression, including upregulation of stress and apoptosis-related genes and downregulation of proliferation, oxidative phosphorylation, and viral-related pathways.
conclusionCEO exerts selective cytotoxic and antiproliferative effects on cervical cancer cells by triggering mitochondria-mediated apoptosis and suppressing HPV oncogenes. These findings support CEO as a potential source of bioactive compounds for complementary strategies against HPV-related malignancies.
Indexed as
Identifiers
42919340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.